RecruitingNCT06724562
IL1 Inhibition in FOP
Studying Fibrodysplasia ossificans progressiva
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of California, San Francisco
- Principal Investigator
- Edward Hsiao, MD, PhDUniversity of California, San Francisco
- Intervention
- Anti-IL1 Therapy(other)
- Enrollment
- 11 enrolled
- Eligibility
- 6-30 years · All sexes
- Timeline
- 2025 – 2027
Study locations (1)
- UCSF, San Francisco, California, United States
Collaborators
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06724562 on ClinicalTrials.govOther trials for Fibrodysplasia ossificans progressiva
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06089616A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)Ipsen
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT06508021A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)Ashibio Inc
- ACTIVE NOT RECRUITINGPHASE3NCT05394116A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)Regeneron Pharmaceuticals
- RECRUITINGPHASE2NCT05090891To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans ProgressivaIncyte Corporation
- RECRUITINGNCT02745158The Fibrodysplasia Ossificans Progressiva (FOP) Connection RegistryThe International FOP Association